Recent advances in the structural biology of GPCRs (G-protein-coupled receptors) have provided insights into their structure and function. Comparisons of the visual and ligand-activated receptors highlight the unique elements of rhodopsin that allow it to function as a highly sensitive dim-light photoreceptor in vertebrates, as well as the common elements that it shares with the large class A GPCR family. However, despite progress, a number of questions remain unanswered about how these receptors are activated.
Rhodopsin is both a highly specialized and prototypical GPCR (G-protein-coupled receptor)
Rhodopsin is the visual pigment responsible for dim-light photoreception in vertebrates [1] [2] [3] . The pioneering work of Wald et al. revealed that rhodopsin contains the 11-cis isomer of the vitamin A aldehyde retinal bound to the protein as a protonated Schiff's base, and that absorption of light leads to a rapid cis-to-trans isomerization [4] . Six decades of research have slowly provided a description of how retinal photoisomerization generates the chemical signal associated with the first step of vision. There are several landmark studies that were central to a molecular description of this process. One of the key discoveries was that rhodopsin shares sequence similarity with the β 2 -adrenergic receptor, and is responsible for activating intracellular G-proteins [5] . These receptors have subsequently been found to be members of the GPCR superfamily of seven TM (transmembrane) helix receptors ( Figure 1 ).
The visual receptor subfamily of GPCRs, which includes rhodopsin, is clearly a unique group of receptors. All visual receptors from humans to squid contain the 11-cis isomer of retinal covalently bound within the interior of the protein.
In pharmacological terms, the 11-cis retinal chromophore acts as an inverse agonist when bound to the receptor and reduces basal activity of the apoprotein opsin to very low levels [6, 7] . Upon light absorption, the retinal isomerizes within 200 fs [8] , and then decays thermally through a series of spectrally distinct intermediates. In the transition from the Meta I (metarhodopsin I) to the Meta II intermediate the receptor undergoes a large conformational change to generate the G-protein-binding pocket on the intracellular side of the receptor. In 1996, EPR studies revealed that there is an outward rotation of the cytoplasmic end of TM helix H6 in the transition to Meta II [9] . The motion of H6 opens up a cavity on the intracellular side of the receptor that serves as the G-protein-binding pocket. The mechanism for how retinal isomerization is coupled to H6 motion, however, only began to be understood once crystal structures of GPCRs were determined starting in 2000 [10] .
Rhodopsin was the first GPCR whose crystal structure was determined to high resolution [10] . The structure confirmed the seven-helix architecture and revealed the location of residues that are conserved across the large class A GPCR family. There were several unexpected features of the structure. On the extracellular side, EL2 (extracellular loop 2) was wedged between the TM helices and served as a cap on the retinal-binding site. On the intracellular side, a short amphipathic helix was found to be oriented roughly perpendicular to the seven TM helices. Since the availability of the rhodopsin structure, the challenge has been to establish how retinal isomerization is linked to changes in the conserved amino acids or in the common structural elements that rhodopsin shares with other members of the class A GPCRs.
In contrast with rhodopsin, the ligand-activated GPCRs selectively bind diffusible ligands, including small organic molecules, hormones, peptides and proteins. In 2007, the first high-resolution crystal structure of a ligand-activated GPCR was determined [11] . More recently, a series of crystal structures have been solved for various GPCRs including the β 1 -adrenergic receptor [12] , dopamine D 3 receptor [13] , histamine H1 receptor [14] , chemokine CXCR4 (CXC chemokine receptor 4) receptor [15] and the adenosine 2a receptor [16] . These receptors were crystallized in their inactive conformations and required site-directed mutagenesis, the creation of chimaeric proteins with T4L (T4 lysozyme) or the co-crystallization with antibody fragments in order to stabilize the receptor. Nevertheless, there is remarkable structural similarity in the position of TM helices and conserved amino acids between these receptors and rhodopsin. The largest differences involve the folding of the extracellular loops, consistent with the role of the extracellular side of the receptor in ligand recognition and discrimination. The sequence of the dim-light photoreceptor rhodopsin is shown highlighting the amino acid positions conserved in the subfamily of visual receptors (green) and across the large class A GPCR family. The 'signature' amino acids (red) are defined as those residues with sequence identities of >70% across the class A GPCR family. The 'group-conserved' residues (blue) are those with conservation of >75% when considered as a group of small and weakly polar residues (alanine, glycine, serine, cysteine and threonine). These amino acids have been identified in membrane proteins as key determinants in helix-helix interactions [40, 41] . The 'subfamily-specific' residues are those that have sequence identities of >90% in one of the 18 subfamilies of class A GPCRs. Each subfamily contains a set of residues that makes it uniquely able to respond to its own ligand. The percentage conservation of amino acids in the class A GPCRs was based on alignment of sequences from the GPCR database (http://www.gpcr.org/7tm/), excluding the large olfactory receptor subfamily.
High-resolution structures of the active state of a GPCR have been more elusive. When exposed to light, crystals of the dark state of rhodopsin dissolve [17] or diffract to only moderate resolution [18] . The first clues to the structural changes occurring upon activation came from crystal structures of opsin that were determined with [19] and without [20] a bound undecapeptide mimic of the C-terminus of G α . The defining feature of the opsin structure was the outward rotation of TM helix H6. However, the crystal structure revealed that the open structure is stabilized by two highly conserved tyrosine residues (Tyr 223 and Tyr 306 ) on helices H5 and H7 that have rotated into the TM bundle and form hydrogen bonds with Arg 135 of the conserved ERY sequence on H3.
Solid-state NMR spectroscopy has also provided several insights into the structure of Meta II [21] . Solid-state NMR has the advantage that Meta II can be trapped at low temperature and the structure characterized through the chemical shift and dipolar interactions [1] . The receptor structure can be probed in membrane environments using the native protein sequence or site-directed mutants. NMR measurements have shown how the retinal chromophore changes position upon activation and triggers a change in hydrogen bonding of His 211 [22] and Trp 265 [23] in the interior of the protein and residues associated with EL2 [24, 25] .
Active-state crystal structures of ligand-activated GPCRs that exhibit a large outward motion of H6 have been determined of the β 2 -adrenergic receptor with either a nanobody [26] or the full-length G-protein bound to the intracellular surface [27] . In the presence of agonist alone, the structural changes in the ligand-activated GPCRs are more modest [16, 28] . Rhodopsin appears to have evolved mechanisms that stabilize the receptor not only in an inactive conformation in the dark but also in a fully active conformation on light absorption. The receptor is a robust on-off switch making use of light energy to bridge two very stable conformations. In contrast, the ligand-activated GPCRs have much smaller barriers to activation. Multiple receptor conformations can be populated, which leads to high basal activity, but also provides versatility in signalling and regulation [29] .
Insights into the activation mechanism of rhodopsin
Despite the multitude of crystal structures of both the visual and ligand-activated receptors, several questions remain unanswered: what is the mechanism by which retinal isomerization (or ligand-binding) and Schiff base deprotonation trigger the large outward motion of H6 on the intracellular side of the receptor? Does the activation mechanism involve a single transition or a series of microswitches? What are the roles of the conserved residues on the extracellular side of the receptor and within the TM core? We re-visit these questions in light of recent structural studies on the active state of rhodopsin by both crystallography and NMR spectroscopy.
What is the role of retinal isomerization?
All visual pigments contain the 11-cis isomer of retinal as their photoreactive chromophore. The retinal is tightly bound to the interior of the protein and the conversion to the trans configuration leads to a rearrangement of surrounding protein residues. There are at least three key aspects of retinal isomerization that are needed for activation. First, isomerization leads to displacement of the β-ionone ring of the retinal towards H5. Structures of Meta II derived from NMR distance measurements and crystallography [30, 31] show that the ring contacts H5 in the region of Met 207 and leads to the rearrangement of a hydrogen-bonding network centred on His 211 [22, 25] . The interaction of the ring with H5 is essential since retinal analogues lacking the β-ionone ring are not able to activate the receptor [32, 33] . There are direct parallels to the role of the catechol ring of ligands that activate the amine receptors. For example, in the β 1 -and β 2 -adrenergic receptors, agonist ligands form hydrogen bonds with serine residues on H5 [26, 28] . A second key aspect of retinal isomerization involves steric interactions of the retinal C19 methyl group with surrounding protein residues. Removal of the methyl group blocks activity [34] , while increasing the size of the methyl group leads to increased dark activity [35] . Finally, retinal isomerization changes the orientation of the protonated Schiff base and triggers the transfer of the Schiff base proton to its Glu 113 counterion on H3 (discussed below).
What is the role of Schiff base deprotonation?
Deprotonation of the Schiff base occurs in the transition of Meta I to Meta II, and is essential for activation [36] . Glu 113 at the extracellular end of H3 is the counterion to the retinal protonated Schiff base and the proton acceptor. Mutation of Glu 113 to glutamine confers constitutive activity on the apo-protein opsin [37] . What is the role of the second extracellular loop?
EL2 is in a key position to regulate the activity of GPCRs, and has been proposed to have roles in ligand binding and regulating helix motion. EL2 adopts different folds in the class A GPCRs whose structures have been determined, consistent with their ligand specificity. In rhodopsin, EL2 folds into two short β-strands (β 3 and β 4 ), which form a cap over the retinalbinding site. Although the fold of EL2 is not conserved, its position is constrained by a conserved disulfide bond between Cys 187 on the β 4 strand and Cys 110 at the extracellular end of H3.
One possible role of EL2 in rhodopsin is to regulate access of the retinal protonated Schiff base to water. The pK a of the Schiff base is high and proton transfer is required for activation. More generally, the EL2 of other GPCRs may regulate the access of ligands. For example, Lys 305 on EL2 in the β 2 -adrenergic receptor interacts with Asp 192 on EL3 [11] . This interaction is the only contact that prevents free access of ligand to the amine-binding site within the TM helix bundle. Upon binding of formoterol, an agonist with nanomolar affinity, the Lys 305 -Asp 192 salt bridge appears to be The crystal structure of dark rhodopsin is shown, which highlights the positions of key structural changes within the retinal binding site upon receptor activation. Residue colours correspond to conservation type (see Figure 1) . weakened [38] consistent with the opening of the extracellular side of the receptor. Changes in the position or hydrogen-bonding interactions involving EL2 may also be coupled to the position of the TM helices. The position of EL2 is stabilized through a series of hydrogen-bonding interactions (Figure 2 [24, 25] .
What is the role of the conserved aromatic cluster on H6?
In order to provide a comprehensive description of the activation mechanism of rhodopsin, one must understand the roles of the residues that are conserved across the class A GPCR family. We have previously emphasized that there are three levels of conservation that one must consider in describing the activation mechanism of rhodopsin or one of the many ligand-activated GPCRs [1] . These are highlighted in Figure 1 .
In [39] . This shift may accommodate pivoting of TM helix H6, but the mechanism is not clear from the structures of Meta II [30, 31] .
Phe 261 plays a pivotal role in the activation of rhodopsin and other class A GPCRs. Phe 261 is located between Trp 265 on H6 and Leu 128 on H3, both of which are signature residues with high sequence identity. In the crystal structure of Meta II [30] , Phe 261 rotates into van der Waals contact with Pro 215 on H5, another signature residue. In the β 2 -adrenergic receptor [26] , the conserved phenylalanine residue (Phe 282 ) of the aromatic cluster rotates towards H5 and repacks against the conserved proline residue on H5, as in Meta II. The observed ratcheting action of this phenylalanine with residues on H3 may represent a key conformational change associated with the outward pivoting of H6.
Summary
Rhodopsin has evolved to function as an off-on switch that is triggered by light. In the dark, rhodopsin has very low basal activity. There are multiple steric, electrostatic and hydrogen-bonding interactions that are broken using approximately 30 kcal/mol (1 kcal = 4.184 kJ) of energy channelled into the protein upon light absorption. New electrostatic and hydrogen-bonding interactions define a stable active conformation to allow amplification of the light signal by a single active receptor through the binding and catalysis of hundreds of G-proteins. Rhodopsin can consequently be seen as the prototypical two-state receptor.
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